An international journal published by K. N. Toosi University of Technology

Document Type : Research Article

Author

Application Radiation Research School‎, ‎Nuclear Science and Technology Research Institute‎, ‎Tehran‎, ‎Iran.

Abstract

‎18F-FDG PET/CT is commonly used for evaluation and diagnostic of many types of cancer‎, ‎such as; tumor diagnosis‎, ‎treatment monitoring‎, ‎and radiation therapy planning‎. ‎Accurate diagnostic is needed in meticulous patient preparation‎, ‎including restrictions of diet and activity and management of blood glucose levels in diabetic patients‎, ‎as well as an awareness of the effect of medications and environmental conditions‎. ‎All of these conditions play important roles toward obtaining good-quality images‎, ‎which are essential for accurate interpretation‎. ‎This article introduces the new synthesis and quality control method for obtaining the best quality FDG which is used as radiopharmaceutical‎. ‎All the reactions are carried out and completed in one reaction vessel without any replacement‎. ‎The paper is including details of synthesis‎, ‎quality control and transportation step‎. ‎It is the first time that the alkaline FDG synthesis is introducing by details in Iran‎.

Highlights

  • 18F-FDG PET/CT is introduced in Iran based on news synthesis according GMP.
  • It is used for diagnostic tumors, treatment monitoring and radiation therapy planning.
  • The synthesis and quality control are described in details.
  • It could be used as reference method for other PET centers.

Keywords

ACR-SPR (2014). ACR-SPR practice parameter for performing FDG-PET/CT in oncology. Reston, VA: American College of Radiology.

Beyer, T., Czernin, J., and Freudenberg, L. S. (2011). Variations in clinical PET/CT operations: results of an international survey of active PET/CT users. Journal of Nuclear Medicine, 52(2):303–310.

Boellaard, R., O’Doherty, M. J., Weber, W. A., et al. (2010). FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 37(1):181.

Delbeke, D., Coleman, R. E., Guiberteau, M. J., et al. (2006). Procedure guideline for tumor imaging with 18F-FDG

PET/CT 1.0. Journal of Nuclear Medicine, 47(5):885–895. Graham, M. M., Badawi, R. D., andWahl, R. L. (2011). Variations in PET/CT methodology for oncologic imaging at US academic medical centers: an imaging response assessment team survey. Journal of Nuclear Medicine, 52(2):311–317.

IAEA (2012). Cyclotron Produced Radionuclides: Operation and Maintenance of Gas and Liquid Targets. Radioisotopes and Radiopharmaceuticals Series No. 4.

IAEA-TECDOC-1310 (2002). Optimization of synthesis and quality control procedures for the preparation of F-18 and

I-123 labelled peptides for nuclear medicine. Jacene, H. A., Leboulleux, S., Baba, S., et al. (2009). Assessment of interobserver reproducibility in quantitative 18FFDG PET and CT measurements of tumor response to therapy. Journal of Nuclear Medicine, 50(11):1760–1769.

Shankar, L. K., Hoffman, J. M., Bacharach, S., et al. (2006). Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. Journal of Nuclear Medicine, 47(6):1059–1066.

Surasi, D. S., Bhambhvani, P., Baldwin, J. A., et al. (2014). 18F-FDG PET and PET/CT patient preparation: a review of the literature. Journal of Nuclear Medicine Technology, 42(1):5–13.